361 related articles for article (PubMed ID: 24410468)
21. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2012 Aug; 1263():1-12. PubMed ID: 22823582
[TBL] [Abstract][Full Text] [Related]
22. Could anti IL12/23 therapy replace anti-TNF biologics?
Ionescu MA; Lipozencić J
Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
[TBL] [Abstract][Full Text] [Related]
23. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
24. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Toussirot E
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
[TBL] [Abstract][Full Text] [Related]
25. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice.
Danese S; Bonovas S; Peyrin-Biroulet L
J Crohns Colitis; 2017 Oct; 11(10):1258-1266. PubMed ID: 28575273
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Arakawa A; Ruzicka T; Prinz JC
JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
[TBL] [Abstract][Full Text] [Related]
27. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Berman HS; Villa NM; Shi VY; Hsiao JL
J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
[TBL] [Abstract][Full Text] [Related]
28. Ustekinumab for the treatment of Crohn's disease.
Hansen T; Targownik LE
Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
[TBL] [Abstract][Full Text] [Related]
29. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
31. Ustekinumab: a novel therapeutic option in Crohn's disease.
Simon EG; Samuel S; Ghosh S; Moran GW
Expert Opin Biol Ther; 2016 Aug; 16(8):1065-74. PubMed ID: 27341173
[TBL] [Abstract][Full Text] [Related]
32. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
Macaluso FS; Orlando A; Cottone M
Expert Opin Biol Ther; 2019 Feb; 19(2):89-98. PubMed ID: 30571147
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.
Benson JM; Sachs CW; Treacy G; Zhou H; Pendley CE; Brodmerkel CM; Shankar G; Mascelli MA
Nat Biotechnol; 2011 Jul; 29(7):615-24. PubMed ID: 21747388
[TBL] [Abstract][Full Text] [Related]
34. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
Ma C; Panaccione R; Khanna R; Feagan BG; Jairath V
Best Pract Res Clin Gastroenterol; 2019; 38-39():101604. PubMed ID: 31327402
[TBL] [Abstract][Full Text] [Related]
35. Anti-IL-12/23 in Crohn's disease: bench and bedside.
Niederreiter L; Adolph TE; Kaser A
Curr Drug Targets; 2013 Nov; 14(12):1379-84. PubMed ID: 24138637
[TBL] [Abstract][Full Text] [Related]
36. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
[TBL] [Abstract][Full Text] [Related]
37. [New biological drugs in the treatment of inflammatory skin diseases].
Mälkönen T
Duodecim; 2014; 130(6):627-34. PubMed ID: 24724461
[TBL] [Abstract][Full Text] [Related]
38. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
[No Abstract] [Full Text] [Related]
39. Long-term safety of ustekinumab for psoriasis.
Kumar N; Narang K; Cressey BD; Gottlieb AB
Expert Opin Drug Saf; 2013 Sep; 12(5):757-65. PubMed ID: 23745965
[TBL] [Abstract][Full Text] [Related]
40. Targeting Specific Immunologic Pathways in Crohn's Disease.
Ramos GP; Faubion WA; Papadakis KA
Gastroenterol Clin North Am; 2017 Sep; 46(3):577-588. PubMed ID: 28838416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
